Center for biologics evaluation and research (cber), biologics effectiveness and safety (best) initiative: development of new and innovative methods for automated reporting for cber-regulated biologic
Ended Awarded Last action
- Contract number
- 75F40119F19002
- Awardee
-
International Business Machines Corporation UEI VV9KH3L99VE3 Part of International Business Machines Corporation
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $7,081,492
Award facts
- Opportunity
-
- FDA18223SOL1196210 Solicitation number
- Biologics Effectiveness and Safety (BEST) Initiative: Development of New and Innovative Methods for Automated Reporting for CBER-Regulated Products Award Notice · Posted May 25, 2018
- Contract value 100% obligated
- $7,081,492.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 518210 Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Time and Materials
- Place of performance
- Westlake, MD 20817, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$205,571 | |
| Supplemental Agreement for work within scope | $1,288,532 | |
| Other Administrative Action | $0 | |
| Original award | $5,998,531 |
About this award
International Business Machines Corporation (IBM) was awarded a $7,081,492.15 delivery order against the Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative master indefinite delivery/indefinite quantity contract by the Department of Health and Human Services Food and Drug Administration. The delivery order is for the development of new and innovative methods for automated reporting to support CBER-regulated biologics and has a completion date of September 26, 2020. There is no set-aside designation. IBM will leverage its expertise in information technology and consulting to assist the FDA's CBER division, which regulates cell and gene therapies, blood, vaccines, and other biologics, in modernizing its reporting processes through September 2020.
Quick answers
Who was awarded contract 75F40119F19002?
75F40119F19002 was awarded to International Business Machines Corporation by Food and Drug Administration (Department of Health and Human Services) on September 27, 2019.
How much is contract 75F40119F19002 worth?
The government has obligated $7,081,492 on 75F40119F19002.
Is contract 75F40119F19002 an order under another contract?
Yes. 75F40119F19002 is a delivery order under 75F40118D10053, an indefinite delivery contract, on BEST Initiative - New and Innovative Methods for Automated Reporting.
Was contract 75F40119F19002 competed?
The extent of competition for 75F40119F19002 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award